JP2025503545A - ハンチントン病を治療するための組成物及び方法 - Google Patents

ハンチントン病を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2025503545A
JP2025503545A JP2024539560A JP2024539560A JP2025503545A JP 2025503545 A JP2025503545 A JP 2025503545A JP 2024539560 A JP2024539560 A JP 2024539560A JP 2024539560 A JP2024539560 A JP 2024539560A JP 2025503545 A JP2025503545 A JP 2025503545A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
level
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503545A5 (cg-RX-API-DMAC7.html
Inventor
モンガン，アン
イェドノック，テッド
カヒル－マクファーランド，エレン
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2025503545A publication Critical patent/JP2025503545A/ja
Publication of JP2025503545A5 publication Critical patent/JP2025503545A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024539560A 2021-12-30 2022-12-29 ハンチントン病を治療するための組成物及び方法 Pending JP2025503545A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163295213P 2021-12-30 2021-12-30
US63/295,213 2021-12-30
US202263349305P 2022-06-06 2022-06-06
US63/349,305 2022-06-06
PCT/US2022/082523 WO2023130001A1 (en) 2021-12-30 2022-12-29 Compositions and methods for treating huntington's disease

Publications (2)

Publication Number Publication Date
JP2025503545A true JP2025503545A (ja) 2025-02-04
JP2025503545A5 JP2025503545A5 (cg-RX-API-DMAC7.html) 2025-12-26

Family

ID=87000332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539560A Pending JP2025503545A (ja) 2021-12-30 2022-12-29 ハンチントン病を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US20250074973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4457244A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503545A (cg-RX-API-DMAC7.html)
KR (1) KR20240126863A (cg-RX-API-DMAC7.html)
AU (1) AU2022425559A1 (cg-RX-API-DMAC7.html)
IL (1) IL313901A (cg-RX-API-DMAC7.html)
MX (1) MX2024008273A (cg-RX-API-DMAC7.html)
WO (1) WO2023130001A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
EP4457244A4 (en) 2026-01-07
EP4457244A1 (en) 2024-11-06
US20250074973A1 (en) 2025-03-06
AU2022425559A1 (en) 2024-07-04
IL313901A (en) 2024-08-01
MX2024008273A (es) 2024-07-19
KR20240126863A (ko) 2024-08-21
WO2023130001A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
TWI564305B (zh) 治療性抗體
JP7837375B2 (ja) ピログルタメートアミロイド－βに対する抗体及びその使用
KR102610592B1 (ko) 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
JP2022023058A (ja) ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
KR102073034B1 (ko) 항cxcr3 항체
TW202227481A (zh) 中和抗sars-cov-2抗體
KR20130101046A (ko) 항-ｃｘｃｌ13 항체 및 이의 이용 방법
US20170173149A1 (en) Binding molecules specific for il-21 and uses thereof
WO2014086365A1 (en) Anti-pad2 antibodies and treatment of autoimmune diseases
US20250109216A1 (en) Compositions and methods for crosslinking fc receptors
AU2013205589A1 (en) Anti-CXCL13 antibodies and associated epitope sequences
JP2024539141A (ja) 筋ジストロフィーを治療するための組成物及び方法
KR20230087572A (ko) 혈액 장애를 치료하기 위한 조성물 및 방법
WO2022046614A1 (en) Methods for reducing maternal autoantibodies
JP2025503545A (ja) ハンチントン病を治療するための組成物及び方法
CN120641121A (zh) 抗papp-a抗体及其使用方法
JP2018506275A (ja) 多発性硬化症の遺伝子発現マーカー及び治療
CN118525031A (zh) 用于治疗亨廷顿氏病的组合物和方法
HK40114489A (zh) 用於治疗亨廷顿氏病的组合物和方法
CN117642424A (zh) 一种含融合蛋白的药物组合物
JP2025516671A (ja) ループス腎炎を治療するための組成物及び方法
CN115916821A (zh) 用于疫苗接种和感染性疾病的治疗的组合物和方法
US20240287164A1 (en) Antibodies specific to nell2 and methods of use
US20130280254A1 (en) Macrophage-synthesized ccl3 promotes breast cancer metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240828

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251218